Abstract
Tumour necrosis factor (TNF) can be induced in experimental animals by injection of Bacillus Calmette-Guérin followed, after one or two weeks, by treatment with lipopolysaccharide (LPS); serum taken a few hours later contains a high concentration of TNF (Carswell et al., 1975). Isolated macrophages, e.g. obtained from placenta, can be activated with interferon-γ (LFN-γ) and 24 h later induced to produce TNF by treatment with LPS. Also monocytic cell lines, such as the human U-937 line or the murine PU-518 line, can be induced under proper conditions to produce TNF (Männel et al., 1980; Fransen et al., 1985; Marmenout et al., 1985). We have cloned and expressed to a high specific activity in E. coli both the human TNF (hTNF) gene (Marmenout et al., 1985) and the murine TNF (mTNF) gene (Fransen et al., 1985). Also the sequence of the rabbit TNF gene has been reported (Ito et al., 1986). TNF obtained from various species is highly homologous (about 80%). The subunit of the mature hTNF is a 157 amino acids long polypeptide (156 amino acids for mTNF). The native protein is a nearly spherical, trimeric molecule, containing 45% β-structure and little or no α-helix (Wingfield et al., 1987). TNF, as its name implies, was originally recognized as a substance causing necrosis of tumours in experimental animals; this was usually demonstrated by means of a methyl-cholanthrene-induced sarcoma, and it may be noted that obtaining effective tumour regression requires a rather strict adherence to a defined treatment protocol. Remarkably (and almost by coincidence as it later turned out), TNF is also selectively toxic to some transformed cell lines. But in the presence of concomitant treatment with interferon (IFN), many more transformed and malignant cell lines become sensitive to the cytotoxic action of TNF (Williamson et al., 1983; Fransen et al., 1986b).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bachwich PR, Chensue SW, Larrick JW, Kunke SL (1986) Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages. Biochem Biophys Res Commun 136: 94–101
Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W (1986) Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 46: 3990–3993
Balkwill FR, Ward BG, Moodie E, Fiers W (1987) Therapeutic potential of tumor necrosis factor-α and γ-interferon in experimental human ovarian cancer. Cancer Res 47: 4755–4758
Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA (1986) Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 83: 4533–4537
Bevilacqua MP, Wheeler ME, Pober JS, Fiers W, Mendrick DL, Cotran RS, Gimbrone MA (1987) Endothelial-dependent mechanisms of leukocyte adhesion: regulation by interleukin 1 and tumor necrosis factor. In: Movat HZ (ed) Leukocyte emigration and its sequelae. Karger, Basel, p 79
Brouckaert PGG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W (1986) In vivo antitumor activity of recombinant human and murine TNF, alone and in combination with murine IFN-γ, on a syngeneic murine melanoma. Int J Cancer 38: 763–769
Brouckaert PG, Everaerdt B, Libert C, Takahashi N, Fiers W (1989) Species specificity and involvement of other cytokines in endotoxic shock action of recombinant tumour necrosis factor in mice. Ag Act (in press)
Brouckaert P, Spriggs DR, Demetri G, Kufe DW, Fiers W (submitted) Circulating interleukin-6 during a continuous infusion of tumour necrosis factor and interferon-γ
Broudy VC, Kaushansky K, Segal GM, Harlan JM, Adamson JW (1986) Tumor necrosis factor type alpha stimulates human endothelial cells to produce granulocyte/macrophage colony stimulating factor. Proc Natl Acad Sci USA 83: 7467–7471
Bussolino F, Camussi G, Baglioni C (1988) Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1α. J Biol Chem 263: 11856–11861
Camussi G, Bussolino F, Salvidio G, Baglioni C (1987) Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med 166: 1390–1404
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666–3670
Collins T, Lapierre LA, Fiers W, Strominger JL, Pober JS (1986) Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci USA 83: 446–450
Content J, De Wit L, Pierard D, Derynck R, De Clercq E, Fiers W (1982) Secretory proteins induced in human fibroblasts under conditions used for the production of interferon p. Proc Natl Acad Sci USA 79: 2768–2772
Coulie PG, Cayphas S, Vink A, Uyttenhove C, Van Snick J (1987) Interleukin-HP1- related hybridoma and plasmacytoma growth factors induced by lipopolysaccharide in vivo. Eur J Immunol 17: 1217–1220
Dayer JM, Beutler B, Cerami A (1985) Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162: 2163–2168
Defilippi P, Poupart P, Tavernier J, Fiers W, Content J (1987) Induction and regulation of mRNA encoding 26-kDa protein in human cell lines treated with recombinant human tumor necrosis factor. Proc Natl Acad Sci USA 84: 4557–4561
Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino A Jr, O’Connor JV (1986) Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163: 1433–1450
Fiers W, Brouckaert P, Devos R, Fransen L, Leroux-Roels G, Remaut E, Suffys P, Tavernier J, Van der Heyden J, Van Roy F (1986a) Lymphokines and monokines in anti-cancer therapy. Cold Spring Harbor Symp Quant Biol 51: 587–595
Fiers W, Brouckaert P, Guisez Y, Remaut E, Van Roy F, Devos R, Fransen L, Leroux-Roels G, Marmenout A, Tavernier J, Van der Heyden J (1986b) Recombinant interferon gamma and its synergism with tumor necrosis factor in the human and mouse systems. In: Stewart II WE, Schellekens H (eds) The biology of the interferon system 1985. Elsevier Science Publishers, Amsterdam, p 241
Fiers W, Brouckaert P, Goldberg AL, Kettelhut I, Suffys P, Tavernier J, Vanhaesebroeck B, Van Roy F (1987) Structure function relationship of tumour necrosis factor and its mechanism of action. In: Ciba Foundation Symposium 131, Tumour necrosis factor and related cytotoxins. John Wiley & Sons, Chichester, p 109
Fiers W, Brouckaert P, Content J, Contreras R, Everaerdt B, Guisez Y, Libert C, Spriggs D, Takahashi N, Tison B, Vandenabeele P, Van Snick J (in press) Interleukin-6: biological function and regulation of the gene expression in vitro and in vivo. Adv. Immunopharmacol 4
Fransen L, Müller R, Marmenout A, Tavernier J, Van der Heyden J, Kawashima E, Chollet A, Tizard R, Van Heuverswyn H, Van Vliet A, Ruysschaert MR, Fiers W (1985) Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression. Nucl Acids Res 13: 4417–4429
Fransen L, Ruysschaert MR, Van der Heyden J, Fiers W (1986a) Recombinant tumour necrosis factor: species specificity for a variety of human and murine transformed cell lines. Cell Immunol 100: 260–267
Fransen L, Van der Heyden J, Ruysschaert R, Fiers W (1986b) Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 22: 419–426
Galanos C, Freudenberg MA, Reutter W (1979) Galactosamine induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 76: 5939–5943
Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA (1985) Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 82: 8667–8671
Gresser I, Belardelli F, Tavernier J, Fiers W, Podo F, Federico M, Carpinelli G, Duvillard P, Prade M, Maury C, Bandu MT, Maunory MT (1986) Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. V. Comparisons with tumor necrosis factor. Int J Cancer 38: 771–778
Haegeman G, Content J, Volckaert G, Derynck R, Tavernier J, Fiers W (1986) Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur J Biochem 159: 625–632
Hepburn A, Boeynaems JM, Fiers W, Dumont JE (1987) Modulation of tumor necrosis factor-α cytotoxicity in L929 cells by bacterial toxins, hydrocortisone and inhibitors of arachidonic acid metabolism. Biochem Biophys Res Commun 149: 815–822
Hirano T, Matsuda T, Hosoi K, Okano A, Matsui H, Kishimoto T (1988) Absence of antiviral activity in recombinant B cell stimulatory factor 2 (BSF-2). Immunol Lett 17: 41–45
Ito H, Yamamoto S, Kuroda S, Sakamoto H, Kajihara J, Kiyota T, Hayashi H, Kato M, Seko M (1986) Molecular cloning and expression in E. coli of the cDNA coding for rabbit tumor necrosis factor. DNA 5: 149–156
Kettelhut I, Fiers W, Goldberg A (1987) The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Nad Acad Sci USA 84: 4273–4277
Kurt-Jones EA, Fiers W, Pober JS (1987) Membrane interleukin 1 induction on human endothelial cells and dermal fibroblasts. J Immunol 139: 2317–2324
Lehmann V, Freudenberg MA, Galanos C (1987) Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med 165: 657–663
Libby P, Ordovas JM, Auger KR, Robbins AH, Birinyi LK, Dinarello CA (1986) Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol 124: 179–185
Männel DN, Moore RN, Mergenhagen SE (1980) Macrophages as a source of tumoricidal activity (tumor-necrotizing factor). Infect Immun 30: 523–530
Mareel M, Dragonetti C, Tavernier J, Fiers W (1988) Tumor selective cytotoxic effects of murine tumor necrosis factor (TNF) and interferon-gamma (IFN-gamma) in organ culture of B16 melanoma cells and heart tissue. Int J Cancer 42: 470–473
Marmenout A, Fransen L, Tavernier J, Van der Heyden J, Tizard R, Kawashima E, Shaw A, Johnson MJ, Semon D, Müller R, Ruysschaert MR, Van Vliet A, Fiers W (1985) Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor. Eur J Biochem 152: 515–522
Marquet RL, IJzermans JNM, De Bruin RWF, Fiers W, Jeekel J (1987) Anti-tumor activity of recombinant mouse tumor necrosis factor ( TNF) on colon cancer in rats is promoted by recombinant rat interferon gamma; toxicity is reduced by indomethacin. Int J Cancer 40: 550–553
Messadi DV, Pober JS, Fiers W, Gimbrone MA, Murphy GF (1987) Induction of an activation antigen on postcapillary venular endothelium in human skin organ culture. J Immunol 139: 1557–1562
Mosselmans R, Hepburn A, Dumont JE, Fiers W, Galand P (1988) Endocytic pathway of recombinant murine tumor necrosis factor in L-929 cells. J Immunol (in press)
Munker R, Gasson J, Ogawa M, Koeffler HP (1986) Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature 323: 79–82
Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D (1986a) Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin Exp Med 163: 1363–1375
Nawroth PP, Stern DM (1986b) Modulation of endothelial cell homostatic properties by tumor necrosis factor. J Exp Med 163: 740–745
Parant F, Fiers W, Parant M (submitted) Absence of species preference of human and murine tumor necrosis factor in toxicity and anti-infectious studies in mice.
Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA (1986) Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 136: 1680–1687
Pober JS, Lapierre LA, Stolpen AH, Brock TA, Springer TA, Fiers W, Bevilacqua TA, Mendrick DL, Gimbrone MA (1987) Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J. Immunol 138: 3319–3324
Poupart P, Vandenabeele P, Cayphas S, Van Snick J, Haegeman G, Kruys V, Fiers W, Content J (1987) B-cell growth modulating and differentiating activity of recombinant human 26 kDa protein (BSF-2, HuIFN-β2, HPGF ). EMBO J 6: 1219–1224
Reis LFL, Le J, Hirano T, Kishimoto T, Vilcek J (1988) Antiviral action of tumor necrosis factor in human fibroblasts is not mediated by B cell stimulatory factor 2/IFN-β 2, and is inhibited by specific antibodies to IFN-β. J Immunol 140: 1566–1570
Stolpen AH, Guinan EC, Fiers W, Pober JS (1986) Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol 123: 16–24
Suffys P, Beyaert R, Van Roy F, Fiers W (1987) Reduced tumour necrosis factor-induced cytotoxicity by inhibitors of the arachidonic acid metabolism. Biochem Biophys Res Commun 149: 735–743
Suffys P, Van Roy F, Fiers W (1988) Tumour necrosis factor and interleukin 1 activate phospholipase in rat chondrocytes. FEBS Lett 232: 24–28
Van Hinsbergh VWM, Kooistra T, Princen HMG, Fiers W, Emeis JJ (1988) Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood (in press)
Van Hinsbergh VWM, Van den Berg EA, Fiers W, Dooijewaard G (submitted) Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells.
Van Snick J, Cayphas S, Szikora JP, Renauld JC, Van Roost E, Boon T, Simpson RJ (1988) cDNA cloning of murine interleukin-HP1: homology with human interleukin 6. Eur J Immunol 18: 193–197
Vilcek J, Palombella VJ, Henriksen-DeStefano D, Swenson C, Feinman R, Hirai M, Tsujimoto M (1986) Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 163: 632–643
Wallach D, Holtmann H, Engelmann H, Nophar Y (1988) Sensitization and desensitization to lethal effects of tumor necrosis factor and EL-1. J Immunol 140:29– 94–2999
Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ (1983) Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 80: 5397–5401
Wingfield P, Pain RH, Craig S (1987) Tumour necrosis factor is a compact trimer. FEBS Lett 211: 179–184
Zavoico GB, Ewenstein BM, Schafer AI, Pober JS (submitted) Interleukin-1 and related cytokines enhance thrombin stimulated PGI2 production in cultured endothelial cells without affecting thrombin-stimulated von Willebrand factor secretion or platelet activating factor biosynthesis.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Fiers, W. et al. (1989). Tumour Necrosis Factor and Interleukin-6: Structure and Mechanism of Action of the Molecular, Cellular and in Vivo Level. In: Lother, H., Dernick, R., Ostertag, W. (eds) Vectors as Tools for the Study of Normal and Abnormal Growth and Differentiation. NATO ASI Series, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74197-5_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-74197-5_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-74199-9
Online ISBN: 978-3-642-74197-5
eBook Packages: Springer Book Archive